Recent News

Jun

14

Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity Imaging shows...

Jun

07

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of...

Jun

02

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it entered a...

View All

Overview

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus fermentum urna dictum sem sollicitudin fringilla. Donec porttitor tristique congue. Vestibulum congue cursus nunc, at convallis augue pulvinar sit amet. Maecenas interdum rhoncus ullamcorper. Aliquam maximus purus in sapien bibendum, ac pulvinar ipsum venenatis. Praesent maximus sapien rhoncus massa tincidunt pretium. Vivamus ornare sem vitae purus efficitur luctus. Maecenas feugiat a lorem sit amet dignissim. Vestibulum varius tincidunt lobortis. Nulla maximus, nisi vitae tempus gravida, urna metus placerat diam, luctus mollis justo augue vel enim. Mauris condimentum convallis diam, eget sodales enim egestas sollicitudin. Donec vitae maximus risus, et euismod risus. Aliquam erat volutpat. Phasellus ultricies ac turpis nec dignissim. In auctor augue massa, vulputate ullamcorper ipsum ultricies non.

Stock Information
NASDAQFUSN
NEVER MISS AN UPDATE